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indicators of mucosal inﬂammation, were comparable in
IBD patients with or without IBS-like symptoms.
A recent study by Jonefj€all et al.2 investigating 94 patients
with ulcerative colitis (UC) in remission came to the same
conclusion. These ﬁndings are in contrast to the ﬁndings of
Keohane et al., who observed signiﬁcantly higher calprotec-
tin levels in IBD patients with IBS-like symptoms.3
In support of the ﬁndings of Berrill et al. and Jonefj€all
et al., we were also unable to demonstrate a signiﬁcant
difference in calprotectin levels among 36 UC patients in
remission, both with and without abdominal pain, reﬂecting
IBS-like symptoms (see Figure 1). However, in UC patients
with abdominal pain, faecal calprotectin levels signiﬁcantly
correlated with pain scores (r = 0.80, P = 0.002).
Furthermore, we demonstrated increased transcription
of the nociceptive signalling molecule TRPV1 in this
group, which also correlated with pain scores.4 This is in
line with the ﬁndings of Akbar et al.5, who demonstrated
that UC patients in remission complaining of abdominal
pain had signiﬁcantly higher numbers of TRPV1-positive
nerve ﬁbres in the rectosigmoid mucosa.
We therefore hypothesise that the potential cause of
IBS-like symptoms in UC patients in remission is not the
sub-clinical inﬂammation per se, but rather the secondary
changes induced during the acute inﬂammatory phase,
which persist during remission. Upregulation of TRPV1
could represent one of these secondary alterations in
mucosal neurobiology responsible for increased peripheral
nociceptive discharge and subsequent pain symptom
development. The reason why this occurs in only a frac-
tion of UC patients in remission remains to be elucidated.
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SIRS, We read with great interest the careful review article
by Lewis and Stine on the use of medications in patients
with advanced liver disease.1 This is a complete practical
guide for clinicians, but some data are lacking. Here, we
will add information about newer antimicrobial agents
utilised in the treatment of antibiotic-resistant bacterial
infections in cirrhotic patients.2
Linezolid (LNZ) is metabolised by non-enzymatic
chemical oxidation mainly into two inactive metabolites,
an aminoethoxyacetic acid and a hydroxyethyl glycine.
Excretion in urine is the dominant route of elimination.
The pharmacokinetics (PK) are not altered in patients
with mild-to-moderate hepatic impairment (Child-Pugh
class A or B); therefore, no dosage adjustments are nec-
essary. PK data are not available for patients with severe
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Figure 1 | Faecal calprotectin levels in ulcerative colitis
(UC) patients in remission with and without abdominal
pain.
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hepatic impairment (Child-Pugh class C). However, no
dosage adjustments are required because it is metabolised
by a non-enzymatic process.3-5
Daptomycin (DAP) is a cyclic lipopeptide derived
from Streptomyces roseosporus as a fermentation product.
It has a minimal hepatic metabolism and it is excreted
primarily unchanged in urine. The PK of DAP are not
altered in subjects with mild-to-moderate hepatic impair-
ment, compared with healthy volunteers, whereas the PK
in patients with severe hepatic impairment have not been
studied; therefore, caution is advised in the patient with
severe hepatic impairment.6, 7
Tigecycline (TGC) is a derivative of minocycline. The
two major metabolic pathways of TGC consist of
glucuronidation, and amide hydrolysis to t-butylamino-
acetic acid and 9-aminominocycline. The major route of
elimination of TGC is faecal, likely via biliary excretion.
Dose adjustment is required for patients with severe
hepatic impairment. In this setting, the initial dose
should be 100 mg followed by a reduced maintenance
dose of 25 mg every 12 h. No dosage adjustments are
necessary in patients with mild-to-moderate hepatic
impairment.8, 9
Finally, dosage adjustments are not required for
doripenem and ceftaroline in patients with hepatic
impairment.4, 10
In conclusion, we hope that this additional informa-
tion can be included in this practical guide and can be
useful to clinicians in the management of antibi-
otic-resistant bacterial infections in cirrhotic patients.
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We appreciate the additional speciﬁc information pro-
vided by Dr Leone and colleagues1 on the use of these
ﬁve antimicrobials in patients with hepatic impairment,
in their letter concerning our recent review.2 The phar-
macokinetic data they provide along with their speciﬁc
dosing recommendations should assist clinicians using
these agents in patients with advanced liver disease. We
encourage Dr Leone and others to publish their clinical
experience with these, as well as other, drug classes and
disorders in order that the database for using drugs in
cirrhosis can continue to be expanded.
ACKNOWLEDGEMENT
The authors’ declarations of personal and ﬁnancial inter-
ests are unchanged from those in the original article.2
REFERENCES
1. Leone S, Rossi M, Bisi L, Gori A, Esposito S. Letter: antibiotic
dose adjustment in patients with advanced liver disease. Aliment
Pharmacol Ther 2013; 38: 561–2.
2. Lewis JH, Stine JG. Review article: prescribing medications in
patients with cirrhosis – a practical guide. Aliment Pharmacol
Ther 2013; 37: 1132–56.
562 Aliment Pharmacol Ther 2013; 38: 559-562
ª 2013 John Wiley & Sons Ltd
Letters to the Editors
